Literature DB >> 17116005

Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours.

S Krüger1, A K Buck, N M Blumstein, S Pauls, H Schelzig, C Kropf, C Schumann, F M Mottaghy, V Hombach, S N Reske.   

Abstract

BACKGROUND: Integrated positron emission tomography (PET)/computed tomography (CT) scanners have been recently introduced in the diagnostic work-up of suspected pulmonary malignancy and demonstrate encouraging results in the staging of nonsmall-cell lung cancer.
OBJECTIVE: To evaluate the usefulness of integrated FDG PET/CT in pulmonary carcinoid tumours.
SETTING: University hospital.
METHODS: We studied 13 patients (mean age +/- 1 SD, 57 +/- 11 years) with pulmonary carcinoid tumours. All patients demonstrated a single pulmonary lesion. Integrated PET/CT scan and surgical resection were performed in all patients.
RESULTS: The pulmonary lesion size ranged from 1.1 to 5.0 cm. Final histological diagnosis confirmed 12 typical and one atypical pulmonary carcinoid. Mean proliferation rate of the typical carcinoids was 1.7 +/- 1.4%. None of the patients had recurrent carcinoid disease or died during follow-up (864 +/- 218 days). Mean standardized uptake value (SUV) of (18)F-fluorodeoxyglucose (FDG) in typical carcinoids was 3.0 +/- 1.5 (range 1.2 - 6.6); SUV in the atypical carcinoid was remarkably high with a value of 8.5. The SUV was lower than 2.5 in 6 of 12 patients (50%). Mediastinal lymph node metastases or extrathoracic metastases were not detected in any patient.
CONCLUSIONS: (18)F-fluorodeoxyglucose PET/CT imaging improves accurate localization of metabolic activity and thus the interpretation of pulmonary lesions on CT. FDG uptake in pulmonary carcinoid tumours is often lower than expected for malignant tumours. Therefore, surgical resection or biopsy of lesions suspected to be carcinoids should be mandatory, even if they show no hypermetabolism on FDG PET images.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116005     DOI: 10.1111/j.1365-2796.2006.01729.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  17 in total

1.  Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.

Authors:  Tarun Jindal; Arvind Kumar; Balasubramanian Venkitaraman; Roman Dutta; Rakesh Kumar
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

Review 2.  PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.

Authors:  Filippo Lococo; Alfredo Cesario; Massimiliano Paci; Angelina Filice; Annibale Versari; Cristian Rapicetta; Tommaso Ricchetti; Giorgio Sgarbi; Marco Alifano; Alberto Cavazza; Giorgio Treglia
Journal:  Tumour Biol       Date:  2014-05-22

3.  Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience.

Authors:  Shamim Ejaz; Rena Vassilopoulou-Sellin; Naifa L Busaidy; Mimi I Hu; Steven G Waguespack; Camilo Jimenez; Anita K Ying; Maria Cabanillas; Maher Abbara; Mouhammed Amir Habra
Journal:  Cancer       Date:  2011-03-15       Impact factor: 6.860

Review 4.  Molecular imaging of neuroendocrine tumors.

Authors:  Jorge A Carrasquillo; Clara C Chen
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

5.  Performance of integrated FDG-PET/CT for differentiating benign and malignant lung lesions--results from a large prospective clinical trial.

Authors:  Sandra Pauls; Andreas K Buck; Gisela Halter; Felix M Mottaghy; Rainer Muche; Christina Bluemel; Susanne Gerstner; Stefan Krüger; Gerhard Glatting; Ludger Sunder-Plassmann; Peter Möller; Hans-Jürgen Brambs; Sven N Reske
Journal:  Mol Imaging Biol       Date:  2008-01-16       Impact factor: 3.488

6.  Is 68Ga-DOTATATE the answer in lung carcinoid? : Case report and review of literature.

Authors:  Amit Bhoil; Bhagwant R Mittal; Shankaramurthy Gayana; Raghava Kashyap; Anish Bhattacharya; Navneet Singh
Journal:  Lung India       Date:  2012-10

7.  Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.

Authors:  Curtis R Chong; Lori J Wirth; Mizuki Nishino; Aileen B Chen; Lynette M Sholl; Matthew H Kulke; Ciaran J McNamee; Pasi A Jänne; Bruce E Johnson
Journal:  Lung Cancer       Date:  2014-08-27       Impact factor: 5.705

Review 8.  The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.

Authors:  Amit Tirosh; Electron Kebebew
Journal:  Future Oncol       Date:  2017-10-26       Impact factor: 3.404

Review 9.  18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.

Authors:  Sona Balogova; Jean-Noël Talbot; Valérie Nataf; Laure Michaud; Virginie Huchet; Khaldoun Kerrou; Françoise Montravers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-16       Impact factor: 9.236

10.  Use of benzodiazepines before (18)F-FDG-PET/CT dual-phase imaging does not decrease the efficacy of the study.

Authors:  Filiz Ozülker; Tamer Ozülker; Tevfik Ozpaçacı
Journal:  Indian J Nucl Med       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.